Esperion Nexlizet Drug Recall: Failed Dissolution Specifications

Take action

Contact the company & request your remedy

Recalling firmEsperion3891 Ranchero Dr Ste 150, N/A · Ann Arbor, MI 48108-2837

No email on file — write to the address above instead.

✎ GovInfoNow plain-language explainer

What happened, in plain English

Esperion is recalling Nexlizet (bempedoic acid and ezetimibe) tablets that failed dissolution tests at 12-month stability. This could affect drug effectiveness over time, though serious injury risks are not described in the recall.

Why it’s dangerous

The tablets failed dissolution specifications, meaning they may not release the active ingredients properly over time. This could lead to reduced effectiveness of the medication after 12 months of storage.

Who’s affected

Prescription drug users who have Nexlizet tablets with lot numbers 1904872 (expiring 1/31/2025) or 1950377 (expiring 6/30/2025). Patients on cholesterol-lowering medication are most at risk.

How to tell if you have this one

Check the lot number on the Nexlizet packaging: 1904872 (expiring 1/31/2025) or 1950377 (expiring 6/30/2025). These tablets were manufactured for prescription use only.

Brand
Esperion
Category
Drug

Based on the official FDA remedy

What to do — step by step

Check Product Lot Number
Look for lot numbers 1904872 or 1950377 on the Nexlizet packaging.

✎ GovInfoNow

Questions people ask

Is this recall dangerous?

The recall states failed dissolution specifications, which could affect drug effectiveness over time, but serious injury risks are not described.

What should I do if I have these tablets?

The recall does not specify a remedy, so contact your doctor or pharmacist for advice on whether to continue using the medication.

How can I tell if I have the recalled product?

Check the lot number on the packaging: 1904872 (expiring 1/31/2025) or 1950377 (expiring 6/30/2025).

Take action

Contact Esperion

We’ve drafted a message you can send Esperion to request your refund or repair — edit it as you like.

✉️ Open in email

Subject: Recall D-1143-2023 — Esperion Esperion

Hello,

I own a Esperion that is covered by recall D-1143-2023 from Esperion.

I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this?

Thank you.

Similar recalls

From people who’ve dealt with this

Experiences, tips, and questions from readers. Every comment is reviewed before it appears.

No comments yet — be the first to share your experience.

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

Official source: FDA Recall #D-1143-2023 (August 16, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1143-2023 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.

Esperion recalls Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc,

Lower-risk recall